1. Loaded Anti-MSLN Antibody, human IgG1 on ProA Biosensor, can bind MSLN/Mesothelin Protein, Human, Recombinant (His) (Cat#TMPY-07107) with an affinity constant of 0.965 nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested).
2. Immobilized Anti-MSLN Antibody, human IgG1 at 2 μg/mL (100 μL/well) can bind MSLN/Mesothelin Protein, Human, Recombinant (His) (Cat#TMPY-07107), the EC50 is 1.0-3.0 ng/mL.

MSLN/Mesothelin Protein, Human, Recombinant (His) is expressed in HEK293 Cells. The accession number is Q13421.

Human

HEK293 Cells

SMRP,MPF,CAK1

A DNA sequence encoding the human MSLN (AAH09272.1) (Glu296-Gly580) was expressed with a polyhistide tag at the C-terminus.

≥ 95% as determined by SDS-PAGE. ≥ 85% as determined by SEC-HPLC.

Please refer to the lot-specific COA.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

The megakaryocyte potentiating factor belongs to the mesothelin family. This family is comprised of several mammalian pre-pro-megakaryocyte potentiating factor precursor (MPF) or mesothelin proteins. Mesothelin is a glycosylphosphatidylinositol-linked glycoprotein highly expressed in mesothelial cells, mesotheliomas, and ovarian cancer, but the biological function of the protein is not known. Megakaryocyte potentiating factor is highly expressed in mesotheliomas, ovarian cancers, and some squamous cell carcinomas (at protein level). It interacts with MUC16 and potentiates megakaryocyte colony formation in vitro. Megakaryocyte potentiating factor is secreted by several mesothelioma cell lines and is frequently elevated in the blood of patients with mesothelioma. Measurement of this protein may be useful in following the response of mesothelioma to treatment.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy